Biochemistry, Genetics and Molecular Biology
Actin
100%
Titin
68%
Cardiac Muscle Cell
65%
Nebulin
49%
Tropomodulin
48%
Myofibril
40%
Heart Ejection Fraction
37%
Skeletal Muscle
36%
Dynamics
30%
Mouse
30%
Tropomyosin
25%
N-Terminus
22%
C-Terminus
19%
Chick
19%
Heart Function
18%
Isoform
17%
Capping Phenomenon
15%
Knockout Mouse
15%
Proband
15%
Spironolactone
14%
Synapsin I
14%
Myogenesis
13%
Desmin
12%
Clinical Trial
11%
RNA-binding Protein
11%
Natriuretic Peptide
11%
Muscle Contraction
10%
Cytoskeleton
10%
Binding Protein
10%
Troponin I
10%
Intermediate Filament
10%
Binding Site
9%
Muscle Function
9%
Signal Transduction
9%
Actinin
9%
Exome Sequencing
9%
Aldosterone
8%
Protein Repeat
8%
Actin-Binding Protein
8%
Immunofluorescence
7%
Genetics
7%
Xenopus
7%
Messenger RNA
7%
Mouse Model
7%
Cyclase
7%
Gene Expression
6%
LIM Domain
6%
CAPN3
6%
Paxillin
6%
Ankyrin Repeat
6%
Spectrin
6%
Tyrosine Kinase Receptor
6%
Creatinine
6%
Myocardin
6%
Explant
6%
Troponin
6%
Ankyrin
6%
Gene Sequence
6%
Focal Adhesion
6%
Maturation
6%
Prevalence
6%
Protein Complexes
6%
Leucine-Rich Repeat
6%
Tension
5%
Embryogenesis
5%
Actin Polymerization
5%
Adrenergic Stimulation
5%
RNA
5%
Multifunctional Protein
5%
Heart Left Ventricle Ejection Fraction
5%
Keyphrases
Heart Failure with Preserved Ejection Fraction (HFpEF)
47%
Heart Failure
46%
Thin Filament
37%
Patients with Heart Failure
29%
Spironolactone
25%
Actin Filaments
22%
Myocytes
22%
TOPCAT Trial
22%
Titin
22%
Tropomodulin
21%
Nebulin
20%
Striated muscle
17%
Z-disc
17%
Heart Failure Hospitalization
17%
TOPCAT
17%
Left Ventricular Ejection Fraction
17%
Confidence Interval
16%
Aldosterone Antagonists
16%
Leiomodin
16%
Chronic Heart Failure
16%
Pointed End
16%
Cardiac Function
16%
Tropomyosin
13%
Cardiovascular Mortality
13%
Sarcomere
12%
Preserved Ejection Fraction
11%
Filament Length
11%
Myofibril
11%
Cardiac muscle
11%
Adverse Outcomes
11%
Hazard Ratio
10%
Filament Assembly
10%
Spectrin
10%
PARAGON-HF
10%
Ejection Fraction
9%
Skeletal muscle
8%
Clinical Outcomes
8%
Actin
8%
Dilated Cardiomyopathy
8%
Chick
8%
Seattle Heart Failure Model
8%
Sacubitril-valsartan
7%
Older Adults
7%
Type 1 Diabetes Mellitus (T1DM)
7%
Placebo
7%
Ventricular Assist Device
7%
Protein Kinase
7%
Renal Function
6%
Adrenergic Receptors
6%
Heart Rate
6%
Randomized Clinical Trial
6%
Myofibril Assembly
6%
Desmin
6%
HSPB7
6%
Bucindolol
6%
Prognostic Importance
6%
Actin Dynamics
6%
Interferon-α (IFN-α)
6%
Cardiac Structure
6%
Frailty
6%
Cytoskeleton
6%
Guideline-directed Medical Therapy
6%
African American
6%
All-cause Mortality
6%
Cardiomyopathy
6%
I-band
5%
Troponin
5%
Hyperkalemia
5%
Contractile Unit
5%
Atrial Fibrillation
5%
Lymphocytes
5%
Beta-blockers
5%
Estimated Glomerular Filtration Rate
5%
Binding Site
5%
Medicine and Dentistry
Heart Failure
80%
Heart Failure with Preserved Ejection Fraction
34%
Aldosterone Antagonist
18%
Cardiovascular System
17%
Ventricular Assist Device
16%
Ejection Fraction
12%
Hazard Ratio
10%
Heart Function
10%
Diastolic Function
9%
Disease
9%
Quality of Life
8%
Heart Graft
8%
Brain Natriuretic Peptide
8%
Spironolactone
8%
Heart Transplantation
8%
Symptom
7%
Adverse Outcome
7%
Interferon
7%
Frailty
7%
Ischemic Heart Disease
6%
Influenza Vaccination
6%
Thin Filament
6%
Dilated Cardiomyopathy
6%
Advanced Therapy
6%
Systolic Function
6%
Systolic Blood Pressure
6%
Echocardiography
6%
Decision Making
6%
Combination Therapy
5%
Diabetes Mellitus
5%
Heart Left Ventricle Ejection Fraction
5%
COVID-19
5%
Systolic Heart Failure
5%
Personalized Medicine
5%